With Increased Fragmentation, U.S. Market for Bacterial Conjunctivitis Drugs to Face Major Setback in Profits, says TMR As the U.S. market for bacterial conjunctivitis drugs becomes increasingly crowded, companies’ profitability faces a major setback, finds a new study by Transparency Market Research (TMR). The growing fragmentation in this market is leading to intense competition among players, leaving them with meager individual shares. New entrants, in spite of having strong research and development capabilities, lack proper financing and capital help, whereas the huge cost burden involved in research and development limits production activities of established participants. In 2013, the top three manufacturers of bacterial conjunctivitis drugs in the U.S. jointly held a share of nearly 57% in the overall market. “In the present scenario, mergers, acquisitions, and strategic alliances between small biotech research organizations and big pharmaceutical firms in the U.S. can prove to be immensely rewarding for the bacterial conjunctivitis drugs market in this country,� an analyst at TMR says.
U.S Bacterial Conjunctivitis Drugs Market to Reach US$439.8 mn by 2024
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.